Last updated on February 2018

Tenofovir Alafenamide (TAF) in Adolescents With Chronic Hepatitis B Virus Infection


Brief description of study

The primary objective of this study is evaluate the safety, tolerability and antiviral activity (HBV DNA < 20 IU/mL) of tenofovir alafenamide (TAF) 25 mg once daily versus placebo through Week 24 in treatment-naive and treatment-experienced adolescent adolescents (aged 12 to < 18 years) with chronic hepatitis B (CHB).

Clinical Study Identifier: NCT02932150

Contact Investigators or Research Sites near you

Start Over

Gilead Study Team

San Francisco, CA United States
  Connect »

Gilead Study Team

Miami, FL United States
  Connect »

Gilead Study Team

Indianapolis, IN United States
  Connect »

Gilead Study Team

Baltimore, MD United States
  Connect »

Gilead Study Team

Omaha, NE United States
  Connect »

Gilead Study Team

Fort Worth, TX United States
  Connect »

Gilead Study Team

Houston, TX United States
  Connect »

Gilead Study Team

San Antonio, TX United States
  Connect »

Gilead Study Team

Seattle, WA United States
  Connect »

Gilead Study Team

Morgantown, WV United States
  Connect »

Gilead Study Team

Hong Kong, Hong Kong
  Connect »

Gilead Study Team

Daegu, Korea, Republic of
  Connect »

Gilead Study Team

Seoul, Korea, Republic of
  Connect »

Gilead Study Team

Kazan, Russian Federation
  Connect »

Gilead Study Team

Krasnoyarsk, Russian Federation
  Connect »

Gilead Study Team

Moscow, Russian Federation
  Connect »

Gilead Study Team

Saint Petersburg, Russian Federation
  Connect »

Gilead Study Team

Tolyatti, Russian Federation
  Connect »

Gilead Study Team

Aurora, CO United States
  Connect »

Gilead Study Team

Kansas City, MO United States
  Connect »

Gilead Study Team

Cincinnati, OH United States
  Connect »

Gilead Study Team

Nashville, TN United States
  Connect »

Gilead Study Team

Dallas, TX United States
  Connect »